三星生物製劑與美國大型製藥公司簽署 22 億美元 CDMO 合約
Samsung Biologics' mega-deal confirms South Korea's emergence as the world's premier biologics CDMO hub, rivaling traditional manufacturing centers in the US and Europe.
2026年2月21日
2 min read
Samsung Biologics IR
規範來源South Korea
完整分析85%
核心变化
三星生物制剂与一家美国主要制药公司签订了其有史以来最大的22亿美元多年期CDMO合同，用于在松岛园区进行生物制剂生产。
Key Figures
784,000 litersTotal capacity of Samsung's Songdo campus upon completion of Plant 4
Source Report
三星生物製劑與一家未揭露的美國大型製藥公司簽署了 22 億美元的 CDMO 合約。
Sigvera Intelligence
核心要點
1$2.2B CDMO contract is Samsung Biologics' largest ever
2Manufacturing at Songdo campus with 784,000L total capacity
3Reinforces South Korea's position as global biologics manufacturing hub
Strategic Implications
Market Impact
Samsung Biologics' mega-deal confirms South Korea's emergence as the world's premier biologics CDMO hub, rivaling traditional manufacturing centers in the US and Europe.
Industry Context
健康科技与生物技术
Where this signal fits in the broader landscape.
41 条行业信号合作
Company Activity查看全部
Source Verification
Verified from official source
PublisherSamsung Biologics IR
發佈日期Feb 21, 2026
來源類型Exchange Filing
來源分類Verified Canonical
信号时间线
首次报道Feb 21, 2026
索引时间Feb 22, 2026
发布时间Feb 23, 2026
https://koreajoongangdaily.joins.com/news/2025-05-26/business/industry/Samsung-Biologics-manufacturing-deals-exceed-22-billion-this-year/2315474
Read Full Source置信度:0.95%
Get cross-language signal intelligence
Get curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
My Notes
Sign in to save notes on signals.
登录